logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 15 of 15 Items
Showing 1 - 15 of 15 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (15)
  • CSV
  • BibTeX
  • EndNote
  • All Results (15)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country multidrug-resistant/rifampicin-resistant tuberculosis cohort

Khan U, Rich M, Franke MF, Lachenal N, Ahmed S,  et al.
2025-08-01 • Clinical Infectious Diseases
2025-08-01 • Clinical Infectious Diseases

BACKGROUND

The 2022 World Health Organization (WHO) guidelines on multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) recommend 6 months of bedaqu...

Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Conference Material
|
Slide Presentation
Conference Material
|
Abstract
Journal Article
|
Research
Journal Article
|
Short Report
Journal Article
|
Commentary
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research

High caseload of Scabies amongst Rohingya refugees in Cox’s Bazar, Bangladesh: a retrospective analysis of the epidemiological and clinical characteristics of cases, July 2022 to November 2023

Alhaffar BA, Islam S, Hoq MI, Das A, Shibloo SM,  et al.
2025-04-09 • PLOS Global Public Health
2025-04-09 • PLOS Global Public Health

Scabies is a dermatological parasitic infestation prevalent in many regions worldwide. Classified as a neglected disease by World Health Organization (WHO) since 2017, it is often ass...

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR/RR-TB cohort

Khan U, Rich M, Franke M, Lachenal N, Ahmed S,  et al.
2024-12-10 • Clinical Infectious Diseases
2024-12-10 • Clinical Infectious Diseases

BACKGROUND

The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...

Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis

Kho S, Seung KJ, Huerga H, Bastard M, Khan PY,  et al.
2024-05-09 • Nature Communications
2024-05-09 • Nature Communications
Sputum culture reversion after conversion is an indicator of tuberculosis (TB) treatment failure. We analyze data from the endTB multi-country prospective observational cohort (NCT032592...

Assessing the feasibility of collaborating with factories to improve work safety in Kamrangirchar, Dhaka, Bangladesh: participatory before-and-after intervention study

Sadique S, Beversluis D, Caleo GNC, Carter W, Chowdhury SM,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023

Assessing the feasibility of collaborating with factories to improve work safety in Kamrangirchar, Dhaka, Bangladesh: participatory before-and-after intervention study

Sadique S, Beversluis D, Caleo GNC, Carter W, Chowdhury SM,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
Addressing occupational injury and disease has been declared a national priority in Bangladesh. However critical gaps remain in improving work safety in small-scale peri...

Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S,  et al.
2020-07-11 • Clinical Infectious Diseases
2020-07-11 • Clinical Infectious Diseases

Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observati...

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S,  et al.
2019-11-02 • Clinical Infectious Diseases
2019-11-02 • Clinical Infectious Diseases
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...

Introducing new and repurposed TB drugs: the endTB experience

Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...

Culture conversion in patients treated with bedaquiline and/or delamanid. A prospective multicountry study

Franke MF, Khan P, Hewison C, Khan U, Huerga H,  et al.
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however, so...

Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs

Huerga H, Khan UT, Bastard M, Mitnick CD, Lachenal N,  et al.
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND
Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...

The multi-drug resistant tuberculosis diagnosis and treatment cascade in Bangladesh

Hossain ST, Isaakidis P, Sagili KD, Islam S, Islam MS,  et al.
2015-06-25 • PLOS One
2015-06-25 • PLOS One
OBJECTIVES
To determine, in areas supported by BRAC, Bangladesh i) the pre-diagnosis and pre-treatment attrition among presumptive and confirmed Multi-Drug Resistant Tuberculosis (MD...

Culture conversion in patients treated with bedaquiline and/or delamanid: A prospective multi-country study

Franke MF, Khan PY, Hewison CCH, Khan UT, Huerga H,  et al.
2020-07-24 • American Journal of Respiratory and Critical Care Medicine
2020-07-24 • American Journal of Respiratory and Critical Care Medicine
BACKGROUND
Bedaquiline and delamanid offer the possibility of more effective and less toxic multidrug-resistant tuberculosis (MDR-TB) treatment. With this treatment, however, some pa...

Setting up pharmacovigilance based on available endTB project data for bedaquiline

Lachenal N, Hewison CCH, Mitnick CD, Lomtadze N, Coutisson S,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
SETTING
Active pharmacovigilance (PV) is recommended for TB programmes, notably for multidrug-resistant TB (MDR-TB) patients treated with new drugs. Launched with the support of UNIT...

Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort

Hewison CCH, Khan UT, Bastard M, Lachenal N, Coutisson S,  et al.
2022-09-15 • Clinical Infectious Diseases
2022-09-15 • Clinical Infectious Diseases
RATIONALE
Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion.

OBJECTIVES
Evaluate safety of longer MDR/RR-TB...